Inheritance Patterns of Canavan Disease
Exploring the nuanced landscape of inheritance patterns in Canavan disease when confronted with the identification of only one mutation.
Article Date
March 5, 2024
This article is featured on another website.
Go to article
September 9, 2024
TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer
September 9, 2024
TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer
October 1, 2024
Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.
October 1, 2024
Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.